No Data
No Data
Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50?
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital analyst Brian Abrahams maintains $Xenon Pharmaceuticals(XENE.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 49.
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 25% Above Its Share Price
Key Insights Xenon Pharmaceuticals' estimated fair value is US$46.69 based on 2 Stage Free Cash Flow to Equity Xenon Pharmaceuticals is estimated to be 20% undervalued based on current share price o
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman
Express News | Xenon Pharmaceuticals Presents Phase 2 X-NOVA Clinical Trial Data Of Azetukalner in Major Depressive Disorder At ASCP 2024 Annual Meeting
Express News | Xenon Pharmaceuticals Presents Data From Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting